NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/19/2024
Back to search
Official data from USPTO
GLIMHAEVO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
11/19/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
02/03/2023
Registration date
11/19/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/19/2024
Last transaction
11/19/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
16
Owner location
Marburg, DE
Examiner
LEE, DOUGLAS
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
CSL Behring GmbH
Representatives
Scott D. Woldow SMITH, GAMBRELL & RUSSELL, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating von Willebrand diseasehemophiliaprimary immunodeficiencyhereditary angioedemafibrinogen deficiencyAlpha 1 antitrypsin deficiencyinflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophiliapharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophiliapharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophiliaa blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodiesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; blood for medical purposes; cell cultures for medical purposescells for medical or clinical use; cell cultures for medical purposesliving cells for medical use; cell cultures for medical purposesstem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditionsrespiratory conditionspneumoniacovid-19influenza; Pharmaceutical preparationsantibody for the treatment of acute respiratory distress syndromeARDS; pharmaceutical preparationsantibody for the treatment of Idiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD; Pharmaceutical preparationsantibody for the treatment of Hereditary AngioedemaHAE; Pharmaceutical preparationsfor the treatment of Hereditary AngioedemaHAErespiratory diseasesacute respiratory distress syndromeARDSIdiopathic Pulmonary FibrosisIPF and Interstitial Lung DiseasesILD
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/19/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/03/2024
PUBO
PUBLISHED FOR OPPOSITION
09/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/14/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/29/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/15/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/15/2024
ALIE
ASSIGNED TO LIE
07/15/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/25/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/07/2023
GNRT
NON-FINAL ACTION E-MAILED
11/07/2023
CNRT
NON-FINAL ACTION WRITTEN
11/07/2023
DOCK
ASSIGNED TO EXAMINER
11/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/22/2023
NWAP
NEW APPLICATION ENTERED
02/07/2023
Continuous trademark protection
Get notified about every new filing that threatens GLIMHAEVO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.